Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents

The method of clam 9, wherein the therapeutic agent comprises a HMG CoA reductase inhibitor.

A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of therapeutic agents, said method comprising:

• determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at baseline or following administration of the therapeutic agent, the marker including at least one of MPO activity, MPO mass, select MPO-generated oxidation products, and combinations thereof, and
• comparing the level of the systemic marker with a predetermined value to monitor the anti-inflammatory and/or antioxidant actions of the therapeutic agent,
• wherein the therapeutic agent is administered to treat disorders where inflammation and/or oxidative damage is linked to pathogenesis of the disorder.

The method of clam 13, wherein the therapeutic agent comprises a HMG CoA reductase inhibitor and wherein the HMG CoA reductase inhibitor is administered to treat cardiovascular disease.

A diagnostic method of monitoring anti-inflammatory and/or antioxidant actions of a HMG CoA reductase inhibitor, said method comprising:

• determining the level of at least one systemic marker indicative of inflammation or oxidation in a bodily sample taken from a subject at baseline or following administration of the HMG CoA reductase inhibitor, the marker including at least one of MPO activity, MPO mass, select MPO-generated oxidation products, and combinations thereof;
• and
• comparing the level of the systemic marker with a predetermined value to monitor the anti-inflammatory and/or antioxidant actions of the HMG CoA reductase inhibitor.